Tenaya Therapeutics Stock Investor Sentiment

TNYA Stock  USD 3.58  0.20  5.29%   
About 74% of Tenaya Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tenaya Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Tenaya Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Tenaya Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Tenaya Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Tenaya Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at news.google.com         
Vanguard Group Inc. Raises Stock Holdings in Tenaya Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
over three months ago at investorplace.com         
TNYA Stock Earnings Tenaya Therapeutics Beats EPS for Q2 2024
sbwire news
over three months ago at news.google.com         
Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Sto...
Google News at Macroaxis
over three months ago at news.google.com         
Nvidia, Alphabet, and Microsoft Are Sinking This Month. Heres a Safer Way to Invest in Artificial In...
Google News at Macroaxis
over three months ago at simplywall.st         
Recent uptick might appease Tenaya Therapeutics, Inc. institutional owners after losing 20 percent o...
Simply Wall St News at Macroaxis
over three months ago at news.google.com         
Acadian Asset Management LLC Sells 115,373 Shares of Tenaya Therapeutics, Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Tenaya Therapeutics CFO Steps Down, Replacement Sought - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
Tenaya Therapeutics, Inc. Receives Consensus Rating of Buy from Analysts - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Tenaya Therapeutics Receives Buy Rating from HC Wainwright - Defense World
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Tenaya Therapeutics Announces Research Leadership Updates
Yahoo News
over three months ago at finance.yahoo.com         
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines RNA Summit
Yahoo News
over three months ago at benzinga.com         
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines RNA Summit
benzinga news
over three months ago at globenewswire.com         
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines RNA Summit
Macroaxis News: globenewswire.com
over six months ago at news.google.com         
Tenaya Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of Per Share - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Tenaya Therapeutics that are available to investors today. That information is available publicly through Tenaya media outlets and privately through word of mouth or via Tenaya internal channels. However, regardless of the origin, that massive amount of Tenaya data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tenaya Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tenaya Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tenaya Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tenaya Therapeutics alpha.

Tenaya Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Column Group Iii Gp, Lp of 2222222 shares of Tenaya Therapeutics at 4.5 subject to Rule 16b-3
09/26/2024
2
Tenaya Therapeutics, Inc. Given Consensus Rating of Buy by Analysts
10/10/2024
3
Acquisition by Burroughs Amy L. of 34000 shares of Tenaya Therapeutics at 2.04 subject to Rule 16b-3
10/18/2024
4
Heres Why Were Watching Tenaya Therapeutics Cash Burn Situation
11/01/2024
5
Disposition of 2258 shares by Chihiro Saito of Tenaya Therapeutics at 2.12 subject to Rule 16b-3
11/18/2024
6
Tenaya Therapeutics Buy Rating Reiterated at HC Wainwright
11/25/2024
7
Tenaya shares retain Buy rating, price target on trial update
11/26/2024
8
Acquisition by Stehman-breen Catherine of 29532 shares of Tenaya Therapeutics at 7.12 subject to Rule 16b-3
12/06/2024
9
Tenaya Therapeutics SWOT analysis gene therapy stock faces pivotal catalysts
12/10/2024

Complementary Tools for Tenaya Stock analysis

When running Tenaya Therapeutics' price analysis, check to measure Tenaya Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenaya Therapeutics is operating at the current time. Most of Tenaya Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenaya Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenaya Therapeutics' price. Additionally, you may evaluate how the addition of Tenaya Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine